BRAF and melanoma: To demonstrate that BRAFV600E is also sufficient to suppress AKT pathway activation in melanoma cells, we transiently expressed BRAFV600E or wild-type BRAF in CHL1 melanoma cells that contain endogenous wild-type BRAF and assessed the induction of pAKT in response to MEK inhibitor treatment.